Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:50 PM
Ignite Modification Date:
2025-12-24 @ 11:50 PM
NCT ID:
NCT04246151
Eligibility Criteria:
Inclusion Criteria:
* Adult patients of 18 years of age or older identified as asymptomatic carriers of C. difficile (i.e. not meeting case definition of C. difficile infection, see below)
* Started on systemic (oral or intravenous) antibiotics for any (presumed) bacterial infection
* Patient must have vitals (heart rate, blood pressure, temperature), estimated creatinine clearance (using the Chronic Kidney Disease Epidemiology equation (CKD-Epi)) and a complete blood count available within 24 hours of enrolment
Exclusion Criteria:
* On a course of systemic antibiotics that had been started more than 72 hours ago (as current evidence suggests that the earlier probiotics are started, the more efficacious they are)
* Patient with C. difficile, i.e. presence of diarrhea (three or more loose or watery stools within 24 hours), or fevers or hypotension from C. difficile infection
* Any patients with contra-indications to probiotics or vancomycin:
* Immunosuppressed (primary or acquired immunodeficiency, including AIDS (defined as AIDS defining condition or cluster of differentiation 4 (CD4) nadir of \<200/ul), hematologic malignancies, long-term systemic corticosteroid treatment, active treatment with chemotherapeutic agents or biologicals, autoimmune diseases, nephrotic syndrome)
* Structural heart disease (e.g. atrial septal defect, ventricular septal defect)
* Gastroesophageal or compromised gut integrity (e.g. short gut syndrome, intestinal injury or dysfunction, inflammatory bowel diseases including current or past history of Crohn's disease and ulcerative colitis)
* Patients on systemic aminoglycosides, ethacrynic acid, polymixin B, or colistin.
* Prior or current hearing loss
* Female patients with known pregnancy or who are planning to get pregnant, or who are breastfeeding
* Patients with end-stage renal diseases defined as an estimated glomerular filtration rate of \<15ml/min, or absence of a current estimated creatinine clearance
* History of an allergic reaction to one of the study drugs, or sensitivity to milk
* Patients started on probiotics or oral vancomycin while in hospital
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04246151
Study Brief:
Protocol Section:
NCT04246151